## Supplemental Digital Content 9

## TABLE: Patient Recruitment by Country (ITT Analysis Set)

| | All Cohorts | | |
|---|---|---|---|
| **Country, n (%)** | **Ceftazidime-avibactam + Metronidazole (N = 61)** | **Meropenem (N = 22)** | **Total (N = 83)** |
| Czech Republic | 7 (11.5) | 5 (22.7) | 12 (14.5) |
| Greece | 2 (3.3) | 3 (13.6) | 5 (6.0) |
| Hungary | 14 (23.0) | 1 (4.5) | 15 (18.1) |
| Poland | 1 (1.6) | 0 | 1 (1.2) |
| Romania | 1 (1.6) | 1 (4.5) | 2 (2.4) |
| Russian Federation | 3 (4.9) | 0 | 3 (3.6) |
| Spain | 14 (23.0) | 2 (9.1) | 16 (19.3) |
| Taiwan | 6 (9.8) | 4 (18.2) | 10 (12.0) |
| Turkey | 6 (9.8) | 1 (4.5) | 7 (8.4) |
| United States of America | 7 (11.5) | 5 (22.7) | 12 (14.5) |

ITT, intent-to-treat